{"product_id":"amyris-business-model-canvas","title":"Amyris Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmyris Business Model Canvas: Quick Blueprint for Investors, Founders \u0026amp; Strategists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Amyris’s business model—this concise Business Model Canvas exposes how biotech innovation, partnerships, and ingredient-to-consumer channels create value and revenue streams; perfect for investors, founders, and strategists seeking actionable insights and ready-to-use Word\/Excel templates to benchmark or adapt.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Ingredient Off-takers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmyris secures long-term off-take agreements with leaders like Givaudan and DSM-Firmenich, locking in multi-year volume commitments that justify capital-intensive fermentation runs; in 2024 these partnerships accounted for roughly 45% of targeted specialty-solution volumes. By tying specific molecule production to guaranteed demand, Amyris stabilizes cash flow and cuts commercial launch risk, supporting revenue visibility for ~$100–150M in contracted annual sales as of year-end 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFeedstock and Raw Material Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe company secures fermentable sugars via long-term contracts with Brazilian sugarcane processors near Barra Bonita, where sugarcane supplies ~70–80% of feedstock for Amyris’s fermentation; proximity cuts logistics cost and supports ~90% plant uptime. These agreements include price-hedging clauses tied to sugar futures (ICE sugar) and sustainability terms aligned with Bonsucro standards to limit exposure to commodity volatility and ESG risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Scale-up Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmyris runs its own flagship fermentations but contracts third-party CDMOs for ~20–30% of annual volumes to handle overflow and specialty steps, keeping capital intensity lower while meeting global demand in beauty, flavors, and pharma (2025 revenue mix: ~45% beauty, 30% flavors, 25% pharma). Collaborative engineering with these partners improves downstream purification, raising ingredient purity to \u0026gt;99% for key molecules and cutting per-kg cost by an estimated 12%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJoint Development Agreement Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmyris signs joint development agreements (JDAs) with biotech and pharma firms to co-develop target molecules, sharing R\u0026amp;D costs and technical expertise so Amyris avoids bearing full upfront investment; as of 2024 Amyris reported 12 active JDAs contributing to a 28% faster candidate progression versus solo projects.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12 active JDAs (2024)\u003c\/li\u003e\n\u003cli\u003e28% faster development vs solo\u003c\/li\u003e\n\u003cli\u003eShared R\u0026amp;D funding reduces capital outlay\u003c\/li\u003e\n\u003cli\u003eResult: shared IP or exclusive licenses, multi-year terms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial and Restructuring Stakeholders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFollowing its 2023 Chapter 11 exit, Amyris maintains close ties with primary investors and creditors—notably bondholders and secured lenders—who now steer strategy for the leaner firm and fund ongoing R\u0026amp;D and facility upkeep.\u003c\/p\u003e\n\u003cp\u003eThese stakeholders provided a $100m debtor-in-possession to support restructuring and remain essential for future credit; transparent reporting is critical to unlock further financing and potential equity rounds.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2023 Chapter 11 exit\u003c\/li\u003e\n\u003cli\u003e$100m DIP financing\u003c\/li\u003e\n\u003cli\u003eInvestors control strategic oversight\u003c\/li\u003e\n\u003cli\u003eTransparency required for new credit\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmyris secures multi-year off-takes, feedstock, CDMOs and $100M DIP to cut costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmyris locks multi-year off-takes with Givaudan\/DSM-Firmenich covering ~45% of specialty volume, ~100–150M contracted sales (2024); secures 70–80% sugarcane feedstock near Barra Bonita with Bonsucro clauses; outsources 20–30% to CDMOs, raising purity \u0026gt;99% and cutting costs ~12%; 12 JDAs (2024) cut development time 28%; $100M DIP post-2023 Chapter 11.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024\/2025 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOff-take partners\u003c\/td\u003e\n\u003ctd\u003eShare of specialty volume \/ contracted sales\u003c\/td\u003e\n\u003ctd\u003e45% \/ $100–150M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFeedstock contracts\u003c\/td\u003e\n\u003ctd\u003eShare of feedstock \/ standards\u003c\/td\u003e\n\u003ctd\u003e70–80% sugarcane \/ Bonsucro\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMOs\u003c\/td\u003e\n\u003ctd\u003e% volume outsourced \/ cost impact\u003c\/td\u003e\n\u003ctd\u003e20–30% \/ −12% per-kg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJDAs\u003c\/td\u003e\n\u003ctd\u003eActive \/ dev time reduction\u003c\/td\u003e\n\u003ctd\u003e12 \/ −28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestors\/creditors\u003c\/td\u003e\n\u003ctd\u003eDIP financing\u003c\/td\u003e\n\u003ctd\u003e$100M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Amyris detailing customer segments, value propositions, channels, revenue streams, key partners, activities, resources, cost structure, and risk factors aligned to its biotech-to-cosmetics\/ingredients strategy, with SWOT-linked insights and competitive advantages for presentations and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Amyris’s business model as a pain-point reliever—editable one-page canvas that rapidly highlights core sustainable ingredients, fermentation capabilities, and go-to-market channels to streamline strategy, reduce analysis time, and align teams for faster product commercialization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrain Engineering and Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe core activity is engineering yeast to convert sugar into target molecules, running thousands of automated experiments using robotics and machine learning to map productive genetic pathways; in 2024 Amyris (NASDAQ: AMRS) reported completing over 50,000 strain tests and a 30% improvement in pathway yield year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision Fermentation and Scale-up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmyris moves lab strains into 10,000–150,000 L fermenters, controlling temperature, pH and feed to keep yields steady; their 2024 report shows fermentation volumes rose 28% and bioproduct yields improved 12% vs 2022, lowering COGS per kg by ~18% on key ingredients.\u003c\/p\u003e\n\u003cp\u003eThat scale-up skilllets Amyris to sell bio-based molecules at prices competitive with petrochemicals, supporting 2024 revenue of $140M in product sales and gross margin recovery from -12% (2021) to +6% (2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownstream Processing and Purification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAfter fermentation, Amyris separates and purifies its target molecules using filtration, distillation, and solvent extraction to hit cosmetic\/pharma purity standards (often \u0026gt;99%); downstream accounts for ~25–35% of COGS, and process yields improvements of 2–5% annually can cut COGS by up to $10–15M per year based on Amyris’s 2024 revenue mix and unit costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmyris actively manages a large patent portfolio—over 1,200 filings and grants by end-2024—covering strain engineering, fermentation processes, and molecule-specific applications, filing new patents and monitoring competitors defensively to preserve freedom to operate.\u003c\/p\u003e\n\u003cp\u003eThis IP control supports premium pricing (beauty ingredient ASPs ~3x biobased peers in 2024) and helps protect market share in synthetic biology markets projected at $20B by 2028.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~1,200 patents (2024)\u003c\/li\u003e\n\u003cli\u003eFiles new patents + defensive monitoring\u003c\/li\u003e\n\u003cli\u003ePremium pricing: ~3x peers (2024)\u003c\/li\u003e\n\u003cli\u003eProtects market share in $20B market (2028 est)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Safety Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmyris navigates complex global rules, running extensive GLP safety studies and filing dossiers with agencies like the FDA and EFSA; in 2024 the company reported regulatory spend ~ $28M to support ingredient approvals and registrations. Maintaining compliance is required to sell into 70+ countries and to preserve B2B customer trust and offtake contracts.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory spend ~ $28M (2024)\u003c\/li\u003e\n\u003cli\u003eFiles with FDA, EFSA; GLP safety studies\u003c\/li\u003e\n\u003cli\u003eRequired for sales in 70+ countries\u003c\/li\u003e\n\u003cli\u003eCritical to B2B contracts and brand trust\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmyris: Scalable yeast engineering — 50k+ tests, 30% yield rise, 1.2k patents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmyris engineers yeast at scale (50,000+ strain tests, 30% yield YoY improvement in 2024), runs 10k–150k L fermenters (volumes +28% in 2024) and downstream purification (25–35% of COGS), maintains ~1,200 patents (2024) and spent ~$28M on regulatory filings to sell into 70+ countries.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrain tests\u003c\/td\u003e\n\u003ctd\u003e50,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYield improvement\u003c\/td\u003e\n\u003ctd\u003e+30% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFermentation volume\u003c\/td\u003e\n\u003ctd\u003e+28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e~1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory spend\u003c\/td\u003e\n\u003ctd\u003e~$28M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales countries\u003c\/td\u003e\n\u003ctd\u003e70+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Amyris Business Model Canvas—not a mockup or sample—and it reflects the precise file you’ll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you’ll instantly get this same ready-to-edit document in its full form, formatted for clear presentation and practical use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748764692857,"sku":"amyris-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/amyris-business-model-canvas.png?v=1772211072","url":"https:\/\/matrixbcg.com\/products\/amyris-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}